NCT07069712 2026-03-10
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
AstraZeneca
Phase 2 Recruiting
Clinical Trials
10 trialsNCT04379596 2026-02-23
DG-03
AstraZeneca
Phase 2 Recruiting
NCT04482309 2026-01-21
DPT02
AstraZeneca
Phase 2 Recruiting
NCT04744831 2026-01-14
DESTINY-CRC02
Daiichi Sankyo
Phase 2 Completed
NCT06630130 2025-12-15
Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
Samsung Medical Center
Phase 2 Recruiting
NCT04989816 2024-11-21
DG-06
AstraZeneca
Phase 2 Completed
NCT05034887 2024-11-19
Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients with HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East
Phase 2 Recruiting
NCT05965479 2024-11-12
DECIPHER
University of Southampton
Phase 2 Recruiting
NCT03329690 2022-03-18
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
Daiichi Sankyo
Phase 2 Completed
NCT03384940 2021-10-18
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)
Daiichi Sankyo
Phase 2 Completed